BECTON DICKINSON MEDICAL SYSTEMS 3ML BD POSIFLUSH¿ HEPARIN LOCK FLUSH SYRINGE, IN 10ML SYRINGE, 100 USP UNITS/ML; PREFILLED HEPARIN FLUSH SYRINGE
|
Back to Search Results |
|
Catalog Number 306514 |
Device Problem
Nonstandard Device (1420)
|
Patient Problem
Bacterial Infection (1735)
|
Event Date 03/13/2018 |
Event Type
Injury
|
Manufacturer Narrative
|
Twelve potential lot numbers were provided for this incident.The information for each lot number is as follows: medical device lot #: 731211n, medical device expiration date: 11/7/2019, device manufacture date: 11/8/2017.Medical device lot #: 708782n, medical device expiration date: 3/27/2019, device manufacture date: 3/28/2017.Medical device lot #: 709772n, medical device expiration date: 4/6/2019, device manufacture date: 4/7/2017.Medical device lot #: 711671n, medical device expiration date: 4/25/2019, device manufacture date: 4/26/2017.Medical device lot #: 713691n, medical device expiration date: 5/15/2019, device manufacture date: 5/16/2017.Medical device lot #: 715371n, medical device expiration date: 6/1/2019, device manufacture date: 6/2/2017.Medical device lot #: 718121n, medical device expiration date: 6/29/2019, device manufacture date: 6/30/2017.Medical device lot #: 721511n, medical device expiration date: 8/2/2019, device manufacture date: 8/3/2017.Medical device lot #: 725471n, medical device expiration date: 9/10/2019, device manufacture date: 9/11/2017.Medical device lot #: 727211n, medical device expiration date: 9/28/2019, device manufacture date: 9/29/2017.Medical device lot #: 728411n, medical device expiration date: 10/10/2019, device manufacture date: 10/11/2017.Medical device lot #: 731211n, medical device expiration date: 11/7/2019, device manufacture date: 11/8/2017.A device evaluation is anticipated, but has not yet begun.Upon completion of the investigation, a supplemental report will be filed.
|
|
Event Description
|
It was reported that a (b)(6) male patient with a diagnosis of neuroblastoma and a tunneled central line had a positive blood culture for serratia marcescens on (b)(6) 2018.The patient was treated and discharged.The pfge patterns for this incident are indistinguishable from the original co outbreak pattern.The device implicated with this incident is a 3ml bd posiflush¿ heparin lock flush syringe, in 10ml syringe, 100 usp units/ml.Out of an abundance of caution and in the interest of public health, bd voluntarily recalled certain lots of bd posiflush¿ heparin lock flush and bd¿ pre-filled normal saline flush syringes due to a potential for contamination with serratia marcescens bacterium.Bd was notified by the u.S.Food and drug administration (fda) and centers for disease control and prevention (cdc) about a potential epidemiological link between catheter related blood stream infections and the s.Marcescens bacterium.Specifically, the fda and cdc identified a potential connection between reports of infection in a small number of patients caused by s.Marcescens across multiple states.Cdc¿s initial investigation found that affected patients had received treatment using certain bd flush products.To date, there is no evidence of bd flush product testing positive for this bacterium.Investigations are ongoing by bd, fda, and cdc.
|
|
Manufacturer Narrative
|
H.6.Investigation summary: prior to the report of infection evaluated in (b)(4), there was no trend for infection cases reported for franklin product.This complaint is part of a new trend which began in (b)(6) 2018.Capa (b)(4) was initiated to address this issue.Although a definitive lot number was not provided, a general dhr review was performed of the potential lots listed.There were no deviations or non-conformances that occurred during the manufacture of the potential lots listed.The sterility lot test results for the potential lots were all acceptable (no growth exhibited).No samples returned.A review of all lot sterility testing performed for product released between april 2015 and may 2018 confirmed that no organism growth was identified for any lots released during the shelf life of this product.Investigation conclusion: the root cause analysis of the reported infection cases under capa (b)(4) has not identified a direct causation between the infections and the bd franklin product.Capa 350041 has been initiated for this issue.
|
|
Event Description
|
It was reported that a 12 year old male patient with a diagnosis of neuroblastoma and a tunneled central line had a positive blood culture for serratia marcescens on (b)(6) 2018.The patient was treated and discharged.The pfge patterns for this incident are indistinguishable from the original co outbreak pattern.The device implicated with this incident is a 3ml bd posiflush¿ heparin lock flush syringe, in 10ml syringe, 100 usp units/ml.Out of an abundance of caution and in the interest of public health, bd voluntarily recalled certain lots of bd posiflush¿ heparin lock flush and bd¿ pre-filled normal saline flush syringes due to a potential for contamination with serratia marcescens bacterium.Bd was notified by the u.S.Food and drug administration (fda) and centers for disease control and prevention (cdc) about a potential epidemiological link between catheter related blood stream infections and the s.Marcescens bacterium.Specifically, the fda and cdc identified a potential connection between reports of infection in a small number of patients caused by s.Marcescens across multiple states.Cdc¿s initial investigation found that affected patients had received treatment using certain bd flush products.To date, there is no evidence of bd flush product testing positive for this bacterium.Investigations are ongoing by bd, fda, and cdc.
|
|
Search Alerts/Recalls
|
|
|